Durable loss of a malignant T-cell clone in a stage IV cutaneous T-cell lymphoma patient treated with high-dose interferon and photopheresis - 07/09/11
Abstract |
Stage IV cutaneous T-cell lymphoma (CTCL) has a notoriously poor prognosis and many treatment options exist. We describe the successful treatment of a case of stage IV CTCL with combination photopheresis and high-dose interferon alfa (IFN⍺). The patient was treated with combination therapy of monthly photopheresis and daily doses of IFN⍺ up to 36 MU. Response to therapy was followed by clinical observation and Southern blot analysis for the detection of a malignant clone. The findings of this case were compared with others using a computer-based literature review. A complete clinical response lasting 64 months was achieved. Clinical relapse was preceded by an increase in the CD4/CD8 ratio and by reappearance of the T-cell receptor gene rearrangement. Combined photopheresis and high-dose IFN⍺ led to a durable and sustained complete response in stage IV CTCL. CD4/CD8 ratios and T-cell gene rearrangements may be helpful in patient management. (J Am Acad Dermatol 1999;41:880-3.)
Le texte complet de cet article est disponible en PDF.Plan
 | This supplement is made possible through an educational grant from Ortho Dermatological to the American Academy of Dermatology. |
| Reprint requests: Daniel A. Davis, MD, University of Alabama at Birmingham, Department of Dermatology, 700 18th St S, Suite 414, Birmingham, AL 35233. E-mail: dadavis@uab.edu |
 | 0190-9622/99/$8.00 + 0 16/4/98277 |
Vol 41 - N° 5S
P. 880-883 - novembre 1999 Retour au numéro
Article précédent
- Exuberant granulation tissue associated with chronic graft-versus-host disease after transplantation of peripheral blood progenitor cells
- Maria A. Barnadas, Salut Brunet, Anna Sureda, Rosario López, Román Curell, Jordi Sierra, Agustí Alomar
- Primary cutaneous B-cell lymphoma with a dermatomal distribution
- Angelo V. Marzano, Emilio Berti, Elvio Alessi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?